Avantor® Reports First Quarter 2025 Results

Core Insights - Avantor, Inc. reported a net sales of $1,581.4 million for the first quarter of 2025, reflecting a 6$64.5 million, up from $60.4 million in the first quarter of 2024, with an adjusted net income of$155.2 million compared to $150.6 million in the prior year [4][20] - Avantor is implementing a comprehensive strategy to enhance its Lab Solutions segment and has increased its cost transformation target to$400 million in gross run-rate savings by the end of 2027 [2][7] Financial Performance - Net sales for the Laboratory Solutions segment were $1,065.0 million, an 8$1,157.1 million in the first quarter of 2024, with an organic decline of 3% [8][28] - The Bioscience Production segment reported net sales of $516.4 million, a 1$522.7 million in the same quarter of 2024, with flat organic sales [8][28] - Adjusted EBITDA for the quarter was $269.5 million, with an adjusted EBITDA margin of 17.0$283.0 million and 16.8% in the prior year [4][20] Cash Flow and Leverage - Operating cash flow was reported at $109.3 million, while free cash flow was$82.1 million for the quarter [5][27] - As of March 31, 2025, adjusted net leverage stood at 3.2x [5][27] Strategic Outlook - The company is facing ongoing funding and policy-related headwinds, particularly affecting its Lab Solutions revenue due to reduced demand in the Education and Government sectors [2][7] - Avantor is committed to accelerating growth and improving performance across its business segments, with a focus on cost management and operational efficiency [2][7]